Investors bite the big pharma hands that feed them
Spending heavily on buybacks and dividends does not mean sector-leading share price performance, Evaluate Vantage finds.
For medtechs seeking deals, it’s hurry up and wait
Last year venture-backed companies waited longer than average for a takeout, and longer than ever for an IPO.
First-quarter biotech risers work hard for the win
Amid a difficult start to the year for the drug development sector, Abbvie, Bayer, Ipsen and Lantheus stand out as stock market gainers.
Outside big pharma, life remains tough for listed developers
A look at stock performances over the first quarter of 2022 shows the extent to which investors have backed away from high-risk drug development.
Freenome aims to take on the big beasts
Forthcoming data in colorectal cancer screening could put the company’s liquid biopsy on the market – but it looks like Guardant might get there first.
Flotations tank in the first quarter
A correction – as long as it is not too severe – might not be a bad thing for the sector.
